



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 6, 2004 (Date of Deposit)

KIRK BAUMEISTER

(Name of applicant, assignee, or Registered Representative)

January 6, 2004

(Date of Signature)

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Giles-Komar, Jill

Lamb, Roberta Mbow, M. Lamine

Serial No.: 10/644,308 Art Unit:

Filed: August 19, 2003 Examiner:

For : METHOD FOR GENERATING ANTIBODIES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

X

accompanied by one of:

In accordance with §1.97(b), since this Information

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [ ] the first or Second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/CEN309 USA NP/KB the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final

Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is

•			Statement in Accordance with §1.97(e)
			(attached); or
•			Please charge Deposit Account No. 10-
			0750/CEN309/KB the fee of \$180.00 as set forth
			in §1.17(p).
	П	In a	ccordance with §1.97(d), this Information
	Disclosur	e Sta	tement is being filed after the mailing date of
	either a	Final	Action under §1.113 or a Notice of Allowance
	under §1	.311	but before the payment of the Issue Fee.
	Applicant	(s) h	ereby petition(s) for consideration of this
	Informati	on Di	sclosure Statement. Included are: Statement in
	Accordanc	e wit	h §1.97(e) as set forth below and the fee of
	\$180.00 a	s set	forth in §1.17(p).
•	57		
		_	es of each of the references listed on the
	attached	Form	PTO-1449 are enclosed herewith.
		Copi	es of references listed on the attached Form PTO-
	1449 are	enclo	sed herewith EXCEPT THAT:
			In view of the voluminous nature of references
			[list as appropriate], and the likelihood that
			these references are available to the Examiner,
			copies are not enclosed herewith.
			If any of the foregoing publications are not
			available to the Examiner, Applicant will
			endeavor to supply copies at the Examiner's
			request.
		Copi	es of only foreign patent documents and non-
	patent li		ure are enclosed in accordance with 37 CFR 1.98
			U.S. patents and each U.S. patent application
			stod on the attached Form PTO-1449 are not

/

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN309/KB. This form is submitted in triplicate.

Respectfully submitted,

KľRK BAUMEISTER Reg. No. 33,833

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610) 240-8465 DATED: January 6, 2004

attached Submission Under MPEP 609 D.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0551-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to resp

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

and to a conection of information unless it displays a valid OND control number.			
Application Number	10/644,308		
Filing Date	AUGUST 19, 2003		
First Named Inventor	JILL GILES-KOMAR		
Group Art Unit			
Examiner Name			
Attorney Docket Number	CEN 309 USA NP		

**U.S. PATENT DOCUMENTS** U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Examiner Cite Kind Code<sup>2</sup> of Cited Document where relevant passages of Cited Document Initials Number (if known) or relevant figures appear No.1 mm-dd-yyyy

#### FOREIGN PATENT DOCUMENTS Date of Publication Foreign Patent Document Pages, Columns, Lines, of Cited Document Name of Patentee or where relevant Examiner Cite passages or relevant mm-dd-yyyy Applicant of Cited Document Initials figures appear Number⁴ KindCode<sup>5</sup> No.1

Examiner		Date	
Signature		Considered	
*EVALUATED	. Initial it reference accompany which the real to the company of the terminal of the company of the terminal of the company of the terminal of the company	4DED 000 D-	the short of the first is and in an element and and

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&#</sup>x27;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

and to a concoder of information unices it disp	hajs a valo onto control number.
Application Number	10/644,308
Filing Date	AUGUST 19, 2003
First Named Inventor	Jill Giles-Komar
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 309 USA NP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	·	LONBERG ET AL, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," Letter to Nature, 1994, 856-859, Vol. 368.	
		GREEN, LARRY, "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies," Journal of Immunological Methods, 1999, 11-23, Vol. 231.	
		LYMAN ET AL, "Molecular Cloning of a Ligand for the flt3/flk-2 Tyrosine Kinase Receptor: A Proliferative Factor for Primitive Hematopoietic Cells," Cell, 1993, 1157-1167, Vol. 75.	
		MARASKOVSKY ET AL, "Dramatic Increase in the Numbers of Functionally Mature Dendritic Cells in Flt3 Ligand-treated Mich: Multiple Dendritic Cell Subpopulations Identified," J. Exp. Med., 1996, 1953-1962, Vol. 184, The Rockefeller University Press.	
		LE BON ET AL, "Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo," Immunity, 2001, 461-470, Vol. 14, Cell Press.	
		COHEN ET AL, "Modulating the immune response to genetic immunization," J. Faseb, 1998, 1611-1626, Vol. 12.	
		ROBINSON, HARRIET, "DNA Vaccines: Basic mechanism and immune responses (Review)," International Journal of Molecular Medicine, 1999, 549-555, Vol. 4.	
		DONNELLY ET AL, "DNA Vaccines," Dev. Biol. Stand., 1998, 43-53, Vol. 95.	
	6		
		·	
			-

Examiner E Signature C	ate onsidered
------------------------	------------------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Alexandria, VA 22313-1450jn.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop: IDS – Patent Applications, Commissioner for Patents, P.

O. Box 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.